Theracryf Company Description

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders.

It develops orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy.

It also develops SFX-01, that has completed phase I for the treatment of brain cancer glioblastoma and neurodevelopmental disorders.

The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024.

Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Theracryf Plc

Country	United Kingdom
Founded	2014
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Huw Jones

Contact Details

Address: Alderley Park Nether Alderley, SK10 4TG United Kingdom
Phone	44 1625 315 090
Website	theracryf.com

Stock Details

Ticker Symbol	TCF
Exchange	London Stock Exchange AIM
Fiscal Year	April - March
Reporting Currency	GBP
ISIN Number	GB00BSVYN304
SIC Code	2836

Key Executives

Name	Position
Huw Jones	Chief Executive Officer
Toni Haenninen	Chief Financial Officer